Quetiapine: A Review of its Use in the Management of Bipolar Depression
CNS Drugs,  Clinical Article

Sanford M et al. – Quetiapine and quetiapine extended–release are valuable additions to the first–line treatments for bipolar depression.

Methods
  • The efficacy and tolerability of quetiapine was evaluated in five 8-week, randomized, double-blind, placebo-controlled, multicentre or multinational trials in patients with a major depressive episode (MDE) associated with bipolar disorder.
  • Across trials, monotherapy with oral quetiapine 300 or 600 mg/day (or quetiapine XR 300 mg/day) produced significantly greater improvements than placebo in depressive symptoms (primary endpoint), according to the change in the Montgomery-Asberg Depression Rating Scale total score.
  • In general, quetiapine and quetiapine XR were also associated with significantly higher MDE response and remission rates than placebo.
  • Across trials, quetiapine and quetiapine XR produced significantly greater improvements in global severity of illness scores than placebo, according to changes in the Clinical Global Impressions scale score.
  • There were no differences in treatment outcomes between quetiapine 300 mg/day and 600 mg/day dosage groups.

Results
  • Patients with bipolar depression who responded to quetiapine during two 8-week acute treatment trials also benefited from continuing quetiapine therapy for up to 52 weeks.
  • Compared with quetiapine responders randomized to placebo, quetiapine responders who continued quetiapine 300 or 600 mg/day had a significantly reduced risk of recurrence of any mood events and of depression mood events, but not of hypomanic/manic events.
  • In a randomized, double-blind, placebo-controlled trial, quetiapine maintenance therapy for up to 104 weeks was more efficacious than placebo or lithium in prolonging the time to recurrence of any mood event (primary endpoint).
  • Patients in this trial had bipolar I disorder with mania, depression or a mixed episode as the index episode, and the trial included only patients who were responsive to acute phase quetiapine, which may have introduced a positive bias in favour of quetiapine over lithium during maintenance therapy.
  • Quetiapine 300 or 600 mg/day and quetiapine XR 300 mg/day was generally well tolerated in patients with bipolar depression, with most treatment-emergent adverse events being of mild to moderate severity.
  • The most frequent adverse events occurring during the acute treatment phase were dry mouth, sedation, somnolence, dizziness (quetiapine and quetiapine XR), constipation (quetiapine) and increased appetite (quetiapine XR).
  • Extrapyramidal symptoms (EPS) occurred across quetiapine and placebo groups, but there were no significant differences between quetiapine and placebo recipients on objective measures of EPS and akathisia.
  • In some trials, quetiapine recipients experienced significantly greater weight gain than placebo recipients.
  • Across trials, some quetiapine recipients had clinically relevant increases in blood glucose or lipid parameters, although these also occurred in patients from other treatment groups.
  • The clinical significance of these changes is uncertain.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Family Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Family Medicine Articles

1 A comparison of the effects of hatha yoga and resistance exercise on mental health and well-being in sedentary adults: A pilot study Complementary Therapies in Medicine, June 11, 2014    Clinical Article

2 Short-term effects of a manual therapy protocol on pain, physical function, quality of sleep, depressive symptoms, and pressure sensitivity in women and men with fibromyalgia syndrome: A randomized controlled trial The Clinical Journal of Pain, June 9, 2014    Clinical Article

3 Depression treatment by withdrawal of short-term low-dose antipsychotic, a proof-of-concept randomized double-blind study Journal of Affective Disorders, June 16, 2014    Clinical Article

4 Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications BMJ, June 12, 2014    Clinical Article

5 A comparison of the effects of hatha yoga and resistance exercise on mental health and well-being in sedentary adults: A pilot study Complementary Therapies in Medicine, June 19, 2014    Clinical Article

6 The effect of green tea on blood pressure and lipid profile: A systematic review and meta-analysis of randomized clinical trials Nutrition, Metabolism & Cardiovascular Diseases, March 27, 2014    Evidence Based Medicine    Review Article

7 Risk of myocardial infarction and stroke in bipolar disorder: A systematic review and exploratory meta-analysis Acta Psychiatrica Scandinavica, May 30, 2014    Evidence Based Medicine    Review Article

8 Impact of mindfulness-based cognitive therapy on health care utilization: a population-based controlled comparison Journal of Psychosomatic Research, June 26, 2014    Clinical Article

9 Prognostic impact of the serum heart-type fatty acid-binding protein (H-FABP) levels in patients admitted to the non-surgical intensive care unit Clinical Research in Cardiology, May 23, 2014    Clinical Article

10 Effect of dietary restriction on peripheral monoamines and anxiety symptoms in obese subjects with metabolic syndrome Psychoneuroendocrinology, June 24, 2014    Clinical Article

11 Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder Neuropsychopharmacology, June 2, 2014    Clinical Article

12 Duloxetine-bupropion combination for treatment-resistant atypical depression: A double-blind, randomized, placebo-controlled trial European Neuropsychopharmacology, May 22, 2014    Clinical Article

13 The association of internet addiction symptoms with anxiety, depression and self-esteem among adolescents with attention-deficit/hyperactivity disorder Comprehensive Psychiatry, June 17, 2014    Clinical Article

14 The impact of anxious symptoms in the remission of depressive symptoms in a clinical trial for depression: Follow-up of six months Journal of Affective Disorders, June 10, 2014    Clinical Article

15 Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression – A systematic review Psychiatry Research, June 18, 2014    Evidence Based Medicine    Review Article

16 Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder Journal of Affective Disorders, June 16, 2014    Evidence Based Medicine    Review Article

17 Changes in circulating leptin levels during acute stress and associations with craving in abstinent smokers: A preliminary investigation Psychoneuroendocrinology, June 20, 2014    Clinical Article

18 Individual mindfulness-based cognitive therapy (MBCT) and cognitive behavior therapy (CBT) for treating depressive symptoms in patients with diabetes: Results of a randomized controlled trial Diabetes Care, June 6, 2014    Clinical Article

19 Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass : a prospective, population-based study JAMA Psychiatry, June 13, 2014    Clinical Article

20 Self-relevant disgust and self-harm urges in patients with borderline personality disorder and depression: A pilot study with a newly designed psychological challenge PLOS ONE, June 27, 2014    Clinical Article

Indexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Medmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close